Study On Clinical Effect And The Difference Of Entecavir In Patients With B And C Genotypes Of Hepatitis B

Background:Study on the efficacy of entecavir antiviral treatment of HBV well is an important part of treatment of antiviral nucleoside analogues.The clinical efficacy of entecavir in the treatment of chronic hepatitis B(CHB)in different clinical stages has been noted.whether or not the B,C genotypes of CHB in different clinical period will influence the antiviral efficacy of entecavir,Currently reported less.Clear and definite the clinical efficacy of entecavir in patients with B and C genotype CHB.The guidance of entecavir in patients with B and C genotypes of hepatitis B clinical medication.To maximize the long-term inhibition of HBV replication,reduce inflammation and necrosis of liver cells,thereby improving the quality of life of patients and prolong their survival time.Especially in the case of other drugs,such as poor efficacy,high drug resistance and poor compliance.By entecavir in between B and C genotypes of CHB patients clinical curative effect observation,It is of great significance to provide theoretical support for the clinical treatment of hepatitis B virus.Objective:To analyze the Efficacy of entecavir in the treatment of patients with hepatitis B virus infection between B and C genotype and compare their difference.Methods:A retrospective analysis was made on the data of meeting a criterion and The standard initial antiviral therapy hospitalized patients with chronic hepatitis B virus hepatitis,decompensated cirrhosis and decompensated cirrhosis.According to the inclusion criteria and exclusion criteria,HBVDNA load,HBs Ag quantitative,TBIL quantitative,ALB quantitative and ALT levels were observed at 4,12,24 and 48 weeks after entecavir treatment in entecavir patients,respectively.After treatment,the seroconversion of HBe Ag and the recurrence of ascites,digestive tract bleeding and hepatic encephalopathy in decompensated cirrhosis were observed.Results:A total of 60 patients with B genotype CHB and C genotype CHB were included in the initial antiviral therapy in this study.(1)Gender distribution:74.37%(119/160)of whom were male,25.63%(41/160)of whom were female,Male: female = 2.9:1;Male had twice as many female who infected HBV.(2)Age distribution: The age beween 30-50 have highest proportion,which accounting for 63.75%(102/160);(3)The baseline level before the treatment of CHB:before the treatment of entecavir,the comparison of HBVDNA,HBs Ag and ALT levels of 160 patients with B and C genotype CHB was no significant difference(P>0.05).But compensatory phase of hepatitis and cirrhosis compared with decompensated liver cirrhosis,there was significant difference in serum total bilirubin(TBIL)and serum albumin(ALB)level(P<0.05).(4)160 cases of hepatitis B patients with HBVDNA load and ALT levels were significantly lower than baseline.At the end of treatment,the rate of HBVDNA conversion was 81.25%,and the recovery rate of ALT was about 78.75%.However,there was no significant difference in HBVDNA load and ALT complex rate between the two groups of B and C genotypes.(5)Compensatory phase of hepatitis and cirrhosis compared with decompensated liver cirrhosis,at 4,12,24 and 48 weeks,HBVDNA negative conversion rate and ALT negative conversion rate were statistically significant(P<0.05).There was no significant difference in HBs Ag negative conversion rate(P>0.05).(6)The effect of B genotype CHB in patients with liver cirrhosis decompensation after entecavir treatment for 48 weeks was significant.Until the end of treatment,Patients with decompensated cirrhosis complicated with ascites,patients with decompensated cirrhosis and cirrhosis and decompensated cirrhosis with hepatic encephalopathy were better than baseline.The difference was statistically significant(P<0.05).And the similar results are obtained on the effect of C genotype CHB in patients with liver cirrhosis decompensation after entecavir treatment for 48 weeks.However,However,there was no significant difference between the B and C two genotypes in the same period(P>0.05).(7)Compared with B and C genotypes in the same period,HBVDNA negative conversion rate,ALT negative conversion rate,ALB complex constant,TBIL complex constant and HBs Ag negative conversion rate did not show significant difference.Conclusion:1.The efficacy of entecavir in the treatment of viral infection was not related to B and C genotypes.